Sotac Pharmaceuticals Receives Purchase Order from Intas for Finished Pharmaceutical Formulations
Sotac Pharmaceuticals Limited has secured a purchase order from Intas Pharmaceuticals Limited, reflecting continued business confidence in the company's offerings. The contract, dated July 22, 2026, is for the supply of various finished pharmaceutical formulations.The total value of the order stands at Rs. 97,57,200/- exclusive of GST. This new order augments Sotac Pharmaceuticals’ existing order book and confirms business relationships with a well-established domestic pharmaceutical entity.
The pharmaceuticals covered under the contract include Entacom 10 Tab, Entacom Plus 100 10 Tab, Entacom Plus 150 10 Tab, and Entacom Plus 50 10 Tab. Each specification of ‘10 Tab’ refers to one strip comprising 10 tablets.
Key commercial details regarding the order are outlined below:
| Detail | Information |
|---|---|
| Client Entity | Intas Pharmaceuticals Limited (Domestic) |
| Order Value | Rs. 97,57,200/- exclusive of GST |
| Payment Terms | After 30 days from the date of receipt of material |
| Delivery Schedule | Staggered supplies between September 05, 2026, and November 05, 2026 |
| Terms of Dispatch | Ex-work |
The transaction confirms that there is no interest of the promoter or promoter group companies in Intas Pharmaceuticals Limited. Furthermore, the order is not classified as a related party transaction.
SOTAC Stock Price Movement
Sotac Pharmaceuticals Limited holds steady at ₹95.10 as of 11:58 AM, maintaining zero percentage movement in live trading. The stock is currently touching its 52-week low, despite having previously recorded a year high of ₹139.65.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.